Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
DRUG
DRUG
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DRUG News
Bright Minds Biosciences Prices 1.945M Shares at $90 for $175.05M Offering
Jan 08 2026
Globenewswire
Innovative Eyewear Inc Reports 45% Year-over-Year Sales Growth in Q4
Jan 07 2026
Benzinga
Bright Minds Biosciences Launches $100 Million Public Offering
Jan 07 2026
Benzinga
Barclays Cuts BJ's Wholesale Price Target to $90
Jan 07 2026
Benzinga
Bright Minds Reports Phase 2 BREAKTHROUGH Trial Results for BMB-101, 73.1% Seizure Reduction
Jan 06 2026
Benzinga
U.S. Stocks Rise as Microchip Technology Raises Q3 Revenue Outlook to $1.185 Billion
Jan 06 2026
Benzinga
Bright Minds' BMB-101 Shows Significant Seizure Reduction in Phase 2 Trial
Jan 06 2026
Globenewswire
Bright Minds Biosciences to Report Phase 2 BMB-101 Results on January 6, 2026
Jan 06 2026
NASDAQ.COM
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
Jan 06 2026
NASDAQ.COM
Bright Minds to Host Conference Call for BMB-101 Phase 2 Results on January 6, 2026
Jan 05 2026
Newsfilter
Understanding the Recent Price Movement of Bright Minds Biosciences Inc. (DRUG) and Its Benefits
Nov 26 2025
NASDAQ.COM
Bright Minds Biosciences to Attend Two Major Healthcare Conferences Focused on CNS Disorders
Nov 25 2025
Newsfilter
Wall Street Experts Predict a 36.27% Increase for Bright Minds Biosciences Inc. (DRUG): Important Insights Before You Invest
Nov 25 2025
NASDAQ.COM
Bright Minds Biosciences Enhances Scientific Advisory Board with Leading Experts in Prader-Willi Syndrome (PWS)
Nov 17 2025
Newsfilter
Bright Minds Biosciences Set to Showcase at Upcoming Conferences
Oct 30 2025
Newsfilter
Expanding Patient Base Fuels Growth for Bright Minds
Sep 08 2025
Benzinga
Show More News
